AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
carbachol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 488 | 51-83-2 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A slowly hydrolyzed CHOLINERGIC AGONIST that acts at both MUSCARINIC RECEPTORS and NICOTINIC RECEPTORS.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 6 | mg | O |
| 0.50 | mg | P |
| 0.40 | ml | None |
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP2K6,MAP3K21,MAP3K7,MAPK7,MAPK9,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CB,PIK3CD,PIK3CG,PIM2,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TTK,ULK1 | 50 | |||
| kinase-selectivity-class | ACVR2B,AXL,BRAF,CAMK2D,CDK4,CDK9,DDR1,EPHB4,FLT3,GRK2,MAP3K21,MAP3K9,MAPK7,SIK2,STK33,TEK,TTK | 17 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 28, 1972 | FDA | ALCON |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | N07AB01 | NERVOUS SYSTEM OTHER NERVOUS SYSTEM DRUGS PARASYMPATHOMIMETICS Choline esters |
| ATC | S01EB02 | SENSORY ORGANS OPHTHALMOLOGICALS ANTIGLAUCOMA PREPARATIONS AND MIOTICS Parasympathomimetics |
| CHEBI has role | CHEBI:35481 | non-narcotic analgesic |
| CHEBI has role | CHEBI:38147 | cardiotonic drug |
| CHEBI has role | CHEBI:38325 | muscarinic agonist |
| CHEBI has role | CHEBI:39456 | antiglaucoma drug |
| CHEBI has role | CHEBI:47958 | nicotinic acetylcholine receptor agonist |
| CHEBI has role | CHEBI:51068 | miotic |
| CHEBI has role | CHEBI:66981 | ophthalmology drug |
| MeSH PA | D000700 | Analgesics |
| MeSH PA | D002316 | Cardiotonic Agents |
| MeSH PA | D002317 | Cardiovascular Agents |
| MeSH PA | D008916 | Miotics |
| MeSH PA | D018377 | Neurotransmitter Agents |
| MeSH PA | D018678 | Cholinergic Agents |
| MeSH PA | D018679 | Cholinergic Agonists |
| MeSH PA | D018689 | Sensory System Agents |
| MeSH PA | D018712 | Analgesics, Non-Narcotic |
| MeSH PA | D020011 | Protective Agents |
Related Drugs by ATC class:
N07AB Choline esters 1 drug
S01EB Parasympathomimetics 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Open-angle glaucoma | indication | 84494001 | DOID:1067 |
| Secondary glaucoma | off-label use | 95717004 | |
| Angle-closure glaucoma | off-label use | 392291006 | DOID:13550 |
| Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
| Peptic ulcer | contraindication | 13200003 | DOID:750 |
| Abdominal pain | contraindication | 21522001 | |
| Parkinsonism | contraindication | 32798002 | |
| Hyperthyroidism | contraindication | 34486009 | DOID:7998 |
| Low blood pressure | contraindication | 45007003 | |
| Bradycardia | contraindication | 48867003 | |
| Heart failure | contraindication | 84114007 | DOID:6000 |
| Asthma | contraindication | 195967001 | DOID:2841 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
None
Orange Book patent data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | 8455494 | May 24, 2030 | TREATMENT OF PRESBYOPIA |
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | 8455494 | May 24, 2030 | TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF BRIMONIDINE AND CARBACHOL ONCE DAILY |
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | 8455494 | May 24, 2030 | USE OF YUVEZZI FOR THE TREATMENT OF PRESBYOPIA IN ADULTS |
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | 12268662 | Nov. 10, 2042 | TREATMENT OF PRESBYOPIA |
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | 12268662 | Nov. 10, 2042 | TREATMENT OF PRESBYOPIA IN ADULTS BY ADMINISTRATION OF BRIMONIDINE AND CARBACHOL ONCE DAILY |
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | 12268662 | Nov. 10, 2042 | USE OF YUVEZZI FOR THE TREATMENT OF PRESBYOPIA IN ADULTS |
Orange Book exclusivity data (new drug applications)
| Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
|---|---|---|---|---|---|---|---|---|---|
| 0.1%;2.75% | YUVEZZI | VISUS | N220142 | Jan. 28, 2026 | RX | SOLUTION/DROPS | OPHTHALMIC | Jan. 28, 2029 | NEW PRODUCT |
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Muscarinic acetylcholine receptor M3 | GPCR | AGONIST | EC50 | 8.70 | WOMBAT-PK | CHEMBL | |||
| Muscarinic acetylcholine receptor M2 | GPCR | EC50 | 7.92 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | EC50 | 7.58 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M5 | GPCR | EC50 | 8.10 | WOMBAT-PK | |||||
| Neuronal acetylcholine receptor subunit alpha-7 | Ion channel | Ki | 4.18 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | Ki | 6.12 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | EC50 | 8.52 | WOMBAT-PK | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 8.40 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.51 | CHEMBL | |||||
| Acetylcholine receptor subunit delta | Ion channel | Ki | 6.35 | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | Ki | 8.10 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M1 | GPCR | Ki | 7.70 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M2 | GPCR | Ki | 8.10 | CHEMBL | |||||
| Muscarinic acetylcholine receptor M4 | GPCR | Ki | 5.59 | CHEMBL | |||||
| Muscarinic acetylcholine receptor | GPCR | Kd | 4.74 | CHEMBL | |||||
| Acetylcholine receptor subunit alpha | Ion channel | IC50 | 5.12 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha2/beta2 | Ion channel | Ki | 6.68 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha3/beta2 | Ion channel | Ki | 5.96 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha3/beta4 | Ion channel | Ki | 5.32 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta2 | Ion channel | Ki | 6.23 | CHEMBL | |||||
| Neuronal acetylcholine receptor; alpha4/beta4 | Ion channel | Ki | 5.89 | CHEMBL | |||||
| Muscarinic acetylcholine receptor | GPCR | Ki | 8.89 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| 4018583 | VUID |
| N0000146899 | NUI |
| D00524 | KEGG_DRUG |
| 1999 | RXNORM |
| C0006945 | UMLSCUI |
| CHEBI:3385 | CHEBI |
| CHEMBL14 | ChEMBL_ID |
| D002217 | MESH_DESCRIPTOR_UI |
| 5831 | PUBCHEM_CID |
| 383 | INN_ID |
| 298 | IUPHAR_LIGAND_ID |
| 8Y164V895Y | UNII |
| 1101 | MMSL |
| 1253 | MMSL |
| 177672 | MMSL |
| 4349 | MMSL |
| 4801 | MMSL |
| 33675006 | SNOMEDCT_US |
| 387183001 | SNOMEDCT_US |
| CCE | PDB_CHEM_ID |
| DB00411 | DRUGBANK_ID |
| 4018583 | VANDF |
| 001690 | NDDF |
| 8Y164V895Y | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| MIOSTAT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0065-0023 | SOLUTION | 0.10 mg | OPHTHALMIC | NDA | 15 sections |
| YUVEZZI | HUMAN PRESCRIPTION DRUG LABEL | 2 | 84892-275 | SOLUTION/ DROPS | 27.50 mg | OPHTHALMIC | NDA | 27 sections |